Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
The accelerated approval is supported by results from part 1 of the ESSENCE trial
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Inclacumab was generally well tolerated in THRIVE-131
Subscribe To Our Newsletter & Stay Updated